{"gene":"PRKAA1","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1996,"finding":"The upstream kinase (later identified as LKB1) phosphorylates the AMPK alpha subunit (PRKAA1) at a single major site, threonine 172, located in the activation segment between the DFG and APE motifs; this phosphorylation is absolutely required for AMP-dependent activation and is antagonized by high ATP concentrations.","method":"In vitro kinase assay with purified rat liver AMPK kinase cascade; site identification by phosphopeptide mapping and mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified enzymes, site-directed identification, replicated extensively","pmids":["8910387"],"is_preprint":false},{"year":2004,"finding":"LKB1 serine/threonine kinase directly phosphorylates Thr-172 on the AMPK alpha subunit (PRKAA1) in vitro and in cells, serving as the dominant upstream activating kinase; LKB1-deficient cells show near-complete loss of Thr-172 phosphorylation and are hypersensitive to energy-stress-induced apoptosis.","method":"In vitro kinase assay; LKB1-knockout MEFs; reintroduction of WT vs kinase-dead LKB1; cell death assay under energy stress","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro phosphorylation plus genetic rescue in LKB1-null cells, replicated across labs","pmids":["14985505"],"is_preprint":false},{"year":2005,"finding":"CaMKKβ (calmodulin-dependent protein kinase kinase beta) is an alternative upstream kinase that phosphorylates and activates AMPK (PRKAA1) in a Ca2+-dependent, AMP-independent manner in LKB1-deficient cells; this represents a Ca2+-dependent neuroprotective pathway.","method":"CaMKK inhibitor STO-609; isoform-specific siRNA knockdown; Ca2+ ionophore stimulation in LKB1-null cells; cell-free kinase assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1 — in vitro assay plus genetic (siRNA) dissection in intact cells, replicated","pmids":["16054095"],"is_preprint":false},{"year":2002,"finding":"Adiponectin activates AMPK (including the alpha1/PRKAA1 subunit) in skeletal muscle and liver, stimulating phosphorylation of acetyl-CoA carboxylase, fatty-acid oxidation, and glucose uptake; dominant-negative AMPK blocks each of these effects, placing PRKAA1 downstream of adiponectin and upstream of ACC and fatty acid oxidation.","method":"Dominant-negative AMPK transfection; in vitro AMPK activity assay; ACC phosphorylation; fatty acid oxidation assay in myocytes; glucose uptake measurement","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays with dominant-negative epistasis, replicated","pmids":["12368907"],"is_preprint":false},{"year":2003,"finding":"AMPK (PRKAA1) phosphorylates TSC2 under energy starvation, enhancing TSC2 activity to suppress mTOR-dependent translation and cell growth; TSC2 phosphorylation by AMPK is required for cell-size control and protection from energy-deprivation-induced apoptosis.","method":"In vitro AMPK kinase assay on TSC2; genetic epistasis with TSC2-null cells; cell size measurement; apoptosis assay under energy stress","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — direct in vitro phosphorylation plus genetic epistasis, independently replicated","pmids":["14651849"],"is_preprint":false},{"year":2005,"finding":"AMPK activation (involving PRKAA1) induces phosphorylation of p53 on serine 15, triggering a G1/S cell-cycle checkpoint in response to glucose deprivation; this AMPK-p53 axis promotes cellular survival during energy stress but drives senescence upon persistent activation.","method":"Pharmacological AMPK activation (AICAR); p53-S15 phosphorylation by immunoblot; cell-cycle analysis; p53-null cell epistasis; glucose deprivation survival assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (pharmacological activation + genetic p53 epistasis + cell cycle), independently replicated","pmids":["15866171"],"is_preprint":false},{"year":2008,"finding":"AMPK (PRKAA1) directly phosphorylates raptor on two conserved serine residues, inducing 14-3-3 binding to raptor; this phosphorylation is required for mTORC1 inhibition and cell-cycle arrest in response to energy stress, revealing raptor as a direct AMPK substrate mediating the metabolic checkpoint.","method":"Proteomic substrate screen; in vitro kinase assay with purified AMPK and raptor; 14-3-3 co-immunoprecipitation; raptor phospho-mutants; cell-cycle analysis in energy-stressed cells","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro phosphorylation, mutagenesis, Co-IP, and functional epistasis in one study","pmids":["18439900"],"is_preprint":false},{"year":2008,"finding":"AMPK alpha1 (PRKAA1) in macrophages suppresses LPS-induced proinflammatory cytokine production (TNF-α, IL-6) and promotes IL-10; dominant-negative AMPKα1 enhances inflammatory responses while constitutively active AMPKα1 reduces them; AMPK negatively regulates IκB-α degradation and positively regulates Akt/CREB signaling.","method":"siRNA knockdown; dominant-negative and constitutively active AMPKα1 transfection in macrophages; cytokine ELISA; IκB-α and Akt phosphorylation by immunoblot","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with multiple downstream readouts in same cell type","pmids":["19050283"],"is_preprint":false},{"year":2014,"finding":"PRKAA1 is required for ULK1 phosphorylation at Ser555 and formation of ULK1-BECN1-PtdIns3K complexes necessary for autophagy-dependent mitochondrial clearance (mitophagy) during erythrocyte maturation; prkaa1−/− mice develop hemolytic anemia, splenomegaly, and shortened erythrocyte lifespan due to accumulation of damaged mitochondria and elevated ROS, all rescued by rapamycin or mitochondria-targeted antioxidant treatment.","method":"prkaa1 knockout mice; bone marrow transplantation; ULK1 Ser555 phosphorylation immunoblot; Co-IP of ULK1-BECN1 complex; autophagic flux assay; mitochondrial content and ROS measurement; hematologic parameters","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with bone marrow transplant rescue, multiple orthogonal mechanistic readouts","pmids":["24988326"],"is_preprint":false},{"year":2014,"finding":"Autophagy is not required for exercise performance or PRKAA1 activation during physical activity, but autophagy (requiring PRKAA1-dependent signaling) is critical for mitochondrial quality control during damaging muscle contraction; this protective effect is gender-specific, primarily affecting females.","method":"Inducible muscle-specific Atg7 knockout mice; treadmill exercise testing; PRKAA1 activity assay; glucose homeostasis measurement; mitochondrial function assay","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — clean inducible KO with defined phenotype, but single lab","pmids":["25483961"],"is_preprint":false},{"year":2015,"finding":"The CAMKK2-PRKAA1-ULK1 signaling pathway is required for CSF1-induced autophagy and human monocyte-to-macrophage differentiation; PRKAA1 links P2RY6 receptor engagement to autophagy induction, and pharmacological P2RY6 agonists can restore autophagy and normal differentiation in CMML patient cells.","method":"siRNA knockdown of CAMKK2, PRKAA1, ULK1 in human monocytes; autophagy flux assay; differentiation markers; P2RY6 agonist treatment; primary CMML patient cells","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — epistatic pathway dissection with multiple siRNA knockdowns plus patient validation","pmids":["26029847"],"is_preprint":false},{"year":2010,"finding":"PRKAA1/2 mediates stress-induced proteasome-dependent loss of ID2 protein in trophoblast stem cells; at low stress levels, PRKAA1/2 mediates metabolic adaptation (ACC inactivation by phosphorylation) without ID2 loss, while higher stress drives irreversible TSC differentiation via ID2 loss.","method":"AMPK inhibitor compound C; PRKAA1/2 siRNA; proteasome inhibitor; ID2 immunoblot; ACC phosphorylation assay; cell accumulation assay in mouse TSCs","journal":"Reproduction (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological and siRNA approaches with defined molecular and phenotypic readouts, single lab","pmids":["20876741"],"is_preprint":false},{"year":2010,"finding":"Benzo(a)pyrene (BaP) activates PRKAA1/2 and causes PRKAA1/2-dependent loss of ID2 protein in trophoblast stem cells in a dose-dependent manner; this occurs at BaP doses equivalent to approximately 2-3 pack/day smoking, suggesting a mechanism for implantation failure in smokers.","method":"AMPK activity assay; PRKAA1/2 siRNA in mouse TSCs; ID2 immunoblot; BaP dose-response; cell proliferation measurement","journal":"Molecular reproduction and development","confidence":"Medium","confidence_rationale":"Tier 3 — siRNA plus pharmacological with defined molecular readout, single lab","pmids":["20422711"],"is_preprint":false},{"year":2010,"finding":"siRNA silencing of PRKAA1 (AMPKα1) in HEK293 cells increases susceptibility to methylmercury toxicity, while AICAR-mediated AMPK activation reduces toxicity, indicating that PRKAA1 phosphorylation/activation plays a protective role against methylmercury-induced cell death.","method":"siRNA knockdown of PRKAA1; AICAR pharmacological activation; cell viability assay after methylmercury treatment","journal":"The Journal of toxicological sciences","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single method (siRNA + pharmacological), no downstream mechanism defined","pmids":["20686348"],"is_preprint":false},{"year":2018,"finding":"Selective endothelial deletion of Prkaa1 reduces glycolysis, compromises endothelial cell proliferation, and accelerates atherosclerotic lesion formation in hyperlipidemic mice; rescue of glycolysis via Slc2a1 (GLUT1) overexpression restores endothelial viability, barrier integrity, and reverses atherosclerosis susceptibility, placing PRKAA1-driven glycolysis upstream of endothelial protection.","method":"Endothelial-specific Prkaa1 knockout mice; atherosclerosis lesion quantification; Slc2a1 overexpression rescue; glycolysis measurement (ECAR); endothelial barrier assay; human EC siRNA knockdown","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific KO, genetic rescue, multiple phenotypic readouts across mouse and human cells","pmids":["30405100"],"is_preprint":false},{"year":2019,"finding":"PRKAA1 promotes gastric cancer cell proliferation and inhibits apoptosis through activation of JNK1 and Akt signaling pathways; pharmacological inhibition (compound C) or shRNA knockdown of PRKAA1 reduces PCNA and Bcl-2 expression and blocks JNK1/Akt activity; inactivation of JNK1 or Akt reverses PRKAA1 overexpression-induced proliferation.","method":"shRNA knockdown; AMPK inhibitor compound C; JNK1/Akt inhibitors; PCNA/Bcl-2 immunoblot; xenograft tumor growth assay in nude mice","journal":"Oncology research","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic and pharmacological approaches with pathway inhibitor epistasis, single lab","pmids":["31558185"],"is_preprint":false},{"year":2019,"finding":"NF-κBp50 transcriptionally regulates PRKAA1 expression in response to H. pylori infection; PRKAA1 in turn activates NF-κB signaling and promotes MMP-2 expression, gastric cancer cell invasion and migration; knockdown of PRKAA1 reduces metastasis in nude mice.","method":"NF-κBp50 siRNA; PRKAA1 stable shRNA knockdown; MMP-2 immunoblot; invasion/migration assay; lung metastasis xenograft model","journal":"Artificial cells, nanomedicine, and biotechnology","confidence":"Medium","confidence_rationale":"Tier 2-3 — epistatic knockdown of NF-κB upstream and PRKAA1 downstream with in vivo validation, single lab","pmids":["31841039"],"is_preprint":false},{"year":2020,"finding":"Energy stress activates AMPK (PRKAA1), which inhibits ferroptosis partly through AMPK-mediated phosphorylation of acetyl-CoA carboxylase (ACC) and consequent reduction of polyunsaturated fatty acid biosynthesis; AMPK inactivation abolishes the protective effects of energy stress on ferroptosis in vitro and in renal ischemia-reperfusion injury in vivo.","method":"AMPK genetic inactivation; energy-stress treatments; ferroptosis assay; lipidomic analysis; ACC phosphorylation; renal IRI mouse model","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — genetic AMPK inactivation with lipidomic mechanistic validation and in vivo model","pmids":["32029897"],"is_preprint":false},{"year":2021,"finding":"Endothelial PRKAA1 deficiency in HFD-fed mice unexpectedly alleviates metabolic syndrome; mechanistically, PRKAA1 knockdown in ECs reduces glycolysis and fatty acid oxidation, decreases acetyl-CoA levels, and suppresses inflammatory gene transcription mediated by ATP citrate lyase and histone acetyltransferase p300.","method":"EC-specific Prkaa1 knockout mice on HFD; metabolic phenotyping; EC glycolysis/FAO measurement; acetyl-CoA quantification; p300 histone acetyltransferase activity; inflammatory gene expression","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific KO with mechanistic dissection through acetyl-CoA/p300 pathway","pmids":["34796475"],"is_preprint":false},{"year":2021,"finding":"Myeloid-specific Prkaa1 deficiency downregulates glucose and lipid metabolism genes in macrophages, impairs their metabolic fitness, and suppresses monocyte/macrophage recruitment to adipose tissue, liver, and arterial walls, reducing atherosclerosis, adipose inflammation, and HFD-induced metabolic disorders.","method":"Myeloid-specific Prkaa1 knockout mice; metabolic gene expression; macrophage glucose/lipid metabolism assays; flow cytometry of tissue macrophages; atherosclerosis lesion quantification","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific KO with metabolic and cellular phenotype, single lab","pmids":["33511118"],"is_preprint":false},{"year":2022,"finding":"FTO demethylase stabilizes PRKAA1 mRNA by reducing m6A modification at the 3'-UTR, preventing YTHDF2-mediated degradation; increased PRKAA1 protein promotes gastric cancer cell growth and glycolysis while suppressing apoptosis by regulating the redox balance (GSH, NADPH levels).","method":"RNA immunoprecipitation (m6A-RIP); YTHDF2 interaction assay with PRKAA1 3'-UTR; FTO siRNA/overexpression; PRKAA1 silencing/overexpression; lactic acid, GSH, NADP+/NADPH measurement; ECAR analysis","journal":"Neoplasma","confidence":"Medium","confidence_rationale":"Tier 2-3 — m6A-RIP and RIP mechanistic experiments, single lab","pmids":["36305690"],"is_preprint":false},{"year":2023,"finding":"PRKAA1 activation induces aberrant PINK1/Parkin-dependent mitophagy in fluoride-exposed neurons; sodium fluoride increases PRKAA1 phosphorylation and upregulates PINK1, Parkin, TOMM20, and Cyt C; both AMPK inhibitor (dorsomorphin) and autophagy inhibitor (3-MA) rescue NaF-induced neuronal apoptosis by restoring normal mitophagic flux.","method":"NaF-treated SH-SY5Y cells and rat model; phosphoproteomics; PINK1/Parkin/TOMM20 immunoblot; autophagic flux assay; dorsomorphin and 3-MA pharmacological rescue; apoptosis assay","journal":"Ecotoxicology and environmental safety","confidence":"Medium","confidence_rationale":"Tier 2-3 — phosphoproteomic identification plus pharmacological epistasis in vitro and in vivo, single lab","pmids":["36924562"],"is_preprint":false},{"year":2017,"finding":"Muscle-specific deletion of Prkaa1 delays skeletal muscle development and, under high-fat diet, leads to enhanced intramyocellular lipid accumulation with upregulation of adipogenic genes and downregulation of mitochondrial oxidation genes; Prkaa1 deletion also activates skeletal muscle mTOR signaling, which contributes to impaired lipid metabolism.","method":"Muscle-specific Prkaa1 knockout mice; HFD feeding; intramyocellular triglyceride quantification; adipogenic and mitochondrial gene expression; mTOR pathway immunoblot; glucose tolerance and insulin sensitivity tests","journal":"Journal of physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — tissue-specific KO with defined metabolic phenotype and pathway analysis, single lab","pmids":["29288408"],"is_preprint":false},{"year":2024,"finding":"GENT (gentiacaulein) inhibits glucose transport, raising the AMP:ATP ratio and activating PRKAA1-mediated autophagy in astrocytes; increased PRKAA1-dependent autophagy enhances clearance of amyloid-β; PRKAA1 knockdown reverses GENT-induced autophagy and anti-inflammatory effects, confirming PRKAA1 as the mechanistic link between energy sensing and Aβ clearance.","method":"Pharmacological glucose transport inhibition; AMP:ATP ratio measurement; PRKAA1 siRNA knockdown; autophagy flux assay; Aβ clearance quantification; NF-κB nuclear translocation assay; cytokine measurement","journal":"Autophagy reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — siRNA epistasis with multiple downstream readouts, single lab","pmids":["40395536"],"is_preprint":false},{"year":2025,"finding":"Selective deletion of Prkaa1 in tendon progenitors causes normal postnatal development but progressive tendon pathology: by one month, widespread transcriptional changes in cell cycle regulation and ECM organization appear; by three months, AMPKα1-deficient tendons show reduced mechanical strength, elevated senescence markers (p21, p16), and eventual ectopic calcification; in vitro, tendon fibroblasts lacking AMPKα1 have altered ECM substrate adhesion; voluntary exercise partially rescues these deficits by improving ECM organization and reducing senescence.","method":"Conditional Prkaa1 knockout in tendon progenitors; RNA sequencing; mechanical tensile testing; senescence marker immunostaining; ectopic calcification histology; ECM adhesion assay; voluntary exercise intervention","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with multiple phenotypic and transcriptomic readouts, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.01.31.635920"],"is_preprint":true},{"year":2017,"finding":"miR-181a targets PRKAA1 in hippocampal neurons (validated by luciferase reporter assay); CFC/OLT training transiently increases miR-181a and decreases PRKAA1 expression/activity; microinjection of PRKAA1 agonist AICAR or inhibitor compound C in the dorsal hippocampus reverses the effects of miR-181a manipulation on memory formation, placing PRKAA1 downstream of miR-181a in hippocampus-dependent memory consolidation.","method":"Luciferase reporter assay; miR-181a agomir/antagomir injection; PRKAA1 activity measurement; AICAR/compound C hippocampal microinjection; fear conditioning and object location behavioral tests","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — luciferase validation plus pharmacological epistasis in vivo with behavioral readout, single lab","pmids":["28814760"],"is_preprint":false}],"current_model":"PRKAA1 encodes the catalytic α1 subunit of AMPK, which is activated by phosphorylation at Thr-172 by upstream kinases LKB1 (energy-stress-dependent) or CaMKKβ (Ca2+-dependent); active PRKAA1 phosphorylates downstream substrates including TSC2, raptor, ACC, and ULK1 to coordinately inhibit mTORC1-driven anabolism, promote autophagy and mitophagy, suppress ferroptosis via ACC-mediated PUFA biosynthesis reduction, regulate macrophage inflammatory polarization, drive protective glycolysis in endothelial cells, maintain erythrocyte homeostasis, and sustain tendon and skeletal muscle metabolic integrity."},"narrative":{"teleology":[{"year":1996,"claim":"Identification of Thr-172 as the single essential activation-loop phosphorylation site on AMPK α resolved how upstream kinase input is transduced into catalytic activation and why AMP dependence requires prior phosphorylation.","evidence":"In vitro kinase assay with purified rat liver AMPK; phosphopeptide mapping and site-directed mutagenesis","pmids":["8910387"],"confidence":"High","gaps":["Identity of the upstream kinase (AMPKK) was unknown","Structural basis of AMP-dependent allosteric activation unresolved","Relative contributions of α1 versus α2 isoforms not distinguished"]},{"year":2004,"claim":"Establishing LKB1 as the dominant upstream kinase for Thr-172 phosphorylation connected the tumor suppressor LKB1 to energy sensing and explained the near-complete loss of AMPK activity in LKB1-deficient cells.","evidence":"In vitro kinase assay; LKB1-knockout MEFs with WT vs kinase-dead LKB1 reintroduction; energy-stress apoptosis rescue","pmids":["14985505"],"confidence":"High","gaps":["Whether alternative kinases can compensate in specific tissues remained unclear","The role of LKB1-associated regulatory subunits (STRAD, MO25) in directing specificity toward PRKAA1 vs PRKAA2 unresolved"]},{"year":2005,"claim":"Discovery of CaMKKβ as a Ca²⁺-dependent, AMP-independent upstream kinase for AMPK revealed a second activation axis, explaining how AMPK can be activated without energy deficit.","evidence":"CaMKK inhibitor STO-609; isoform-specific siRNA; Ca²⁺ ionophore stimulation in LKB1-null cells; cell-free kinase assays","pmids":["16054095"],"confidence":"High","gaps":["Relative in vivo contribution of CaMKKβ vs LKB1 in different tissues not quantified","Other potential upstream kinases not excluded"]},{"year":2002,"claim":"Positioning PRKAA1 as a required mediator downstream of adiponectin and upstream of ACC phosphorylation and fatty acid oxidation established the first complete hormonal–AMPK–metabolic effector axis in muscle and liver.","evidence":"Dominant-negative AMPK epistasis; ACC phosphorylation; fatty acid oxidation and glucose uptake in myocytes","pmids":["12368907"],"confidence":"High","gaps":["Whether PRKAA1 or PRKAA2 is the predominant isoform mediating adiponectin effects in vivo was not resolved","Receptor-to-AMPK signaling intermediates were unknown"]},{"year":2003,"claim":"Identification of TSC2 as a direct AMPK substrate linked energy sensing to growth control via mTOR, explaining how energy deprivation suppresses cell size and translation.","evidence":"In vitro AMPK kinase assay on TSC2; TSC2-null cell epistasis; cell size and apoptosis measurement","pmids":["14651849"],"confidence":"High","gaps":["Whether AMPK phosphorylation of TSC2 is sufficient or requires cooperation with other TSC2 kinases","Direct in vivo relevance in tissue-specific contexts not shown"]},{"year":2005,"claim":"AMPK-dependent phosphorylation of p53 at Ser-15 connected the metabolic checkpoint to cell-cycle arrest, revealing that persistent AMPK activation can drive senescence rather than just survival.","evidence":"AICAR activation; p53-S15 phosphorylation; cell-cycle analysis; p53-null epistasis; glucose deprivation","pmids":["15866171"],"confidence":"High","gaps":["Whether AMPK phosphorylates p53 directly or via intermediate kinases was not fully delineated","Threshold distinguishing protective arrest from senescence undefined"]},{"year":2008,"claim":"Identification of raptor as a direct AMPK substrate that recruits 14-3-3 upon phosphorylation provided a second, TSC2-independent mechanism for mTORC1 inhibition and clarified the multi-pronged nature of AMPK's control over growth.","evidence":"Proteomic substrate screen; in vitro kinase assay; 14-3-3 Co-IP; raptor phospho-mutant rescue; cell-cycle analysis","pmids":["18439900"],"confidence":"High","gaps":["Relative quantitative contribution of raptor vs TSC2 phosphorylation to mTORC1 suppression unknown","Whether 14-3-3 binding is reversible and how it is terminated unclear"]},{"year":2008,"claim":"Demonstrating that PRKAA1 suppresses NF-κB-driven proinflammatory cytokines (TNF-α, IL-6) and promotes IL-10 in macrophages established a direct immune-regulatory role for the α1 isoform beyond metabolic regulation.","evidence":"Reciprocal gain/loss-of-function (dominant-negative and constitutively active AMPKα1) in macrophages; cytokine ELISA; IκB-α and Akt phosphorylation","pmids":["19050283"],"confidence":"High","gaps":["Direct phosphorylation substrates mediating anti-inflammatory output not identified","In vivo relevance in infection or sterile inflammation not tested"]},{"year":2014,"claim":"Showing that PRKAA1 is essential for ULK1-Ser555 phosphorylation, BECN1 complex formation, and mitophagic clearance of mitochondria during erythropoiesis — with knockout mice developing hemolytic anemia — established a non-redundant physiological requirement for the α1 isoform in terminal differentiation.","evidence":"Prkaa1 knockout mice; bone marrow transplantation; ULK1-BECN1 Co-IP; mitochondrial content and ROS measurement; rapamycin rescue","pmids":["24988326"],"confidence":"High","gaps":["Why PRKAA2 cannot compensate for PRKAA1 in erythroid cells is mechanistically unresolved","Precise signaling events linking PRKAA1 to ULK1-BECN1 assembly not fully mapped"]},{"year":2015,"claim":"Epistatic pathway dissection placed CaMKK2–PRKAA1–ULK1 as a required signaling axis for CSF1-induced autophagy during monocyte-to-macrophage differentiation, extending the mitophagy role to myeloid lineage commitment and identifying therapeutic restoration in CMML.","evidence":"Sequential siRNA knockdown of CAMKK2, PRKAA1, ULK1 in human monocytes; autophagy flux; differentiation markers; P2RY6 agonist rescue in CMML patient cells","pmids":["26029847"],"confidence":"High","gaps":["Whether PRKAA1-dependent autophagy is required for all macrophage subtypes or only M-CSF-derived","Long-term efficacy of P2RY6 agonism in CMML patients unknown"]},{"year":2017,"claim":"Muscle-specific Prkaa1 deletion revealed that the α1 isoform maintains mitochondrial oxidative gene expression and prevents intramyocellular lipid accumulation, with mTOR hyperactivation as a contributing mechanism, extending PRKAA1's tissue-specific roles to skeletal muscle lipid homeostasis.","evidence":"Muscle-specific Prkaa1 knockout mice; HFD feeding; triglyceride and gene expression; mTOR pathway immunoblot","pmids":["29288408"],"confidence":"Medium","gaps":["Relative contribution of PRKAA1 vs PRKAA2 in skeletal muscle lipid metabolism not clarified","Whether mTOR inhibition alone rescues the lipid phenotype not tested","Single-lab observation"]},{"year":2018,"claim":"Endothelial-specific Prkaa1 deletion showed that PRKAA1-driven glycolysis is required for endothelial proliferation and barrier integrity, and its loss accelerates atherosclerosis — a phenotype rescued by GLUT1 overexpression — establishing the α1 isoform as a vascular metabolic gatekeeper.","evidence":"EC-specific Prkaa1 KO mice; atherosclerosis quantification; GLUT1 rescue; ECAR measurement; barrier assays","pmids":["30405100"],"confidence":"High","gaps":["Molecular targets through which PRKAA1 upregulates GLUT1 expression not identified","Interaction with endothelial PRKAA2 not addressed"]},{"year":2020,"claim":"Demonstrating that AMPK inhibits ferroptosis via ACC phosphorylation and consequent reduction of PUFA biosynthesis linked the classical AMPK-ACC axis to a novel cell death modality and provided in vivo validation in renal ischemia-reperfusion injury.","evidence":"Genetic AMPK inactivation; ferroptosis and lipidomic analysis; ACC phosphorylation; renal IRI model","pmids":["32029897"],"confidence":"High","gaps":["Whether PRKAA1 or PRKAA2 is the dominant isoform in ferroptosis suppression not distinguished","Other AMPK substrates contributing to ferroptosis resistance not excluded"]},{"year":2021,"claim":"Dual context-dependent vascular roles emerged: endothelial PRKAA1 deficiency in HFD reduces acetyl-CoA and p300-mediated inflammatory transcription (improving metabolic syndrome), while myeloid PRKAA1 deficiency impairs macrophage metabolic fitness and tissue recruitment (reducing atherosclerosis), revealing opposing cell-type-specific outcomes.","evidence":"EC-specific and myeloid-specific Prkaa1 KO mice on HFD; acetyl-CoA and p300 activity; macrophage metabolomics; flow cytometry; atherosclerosis and metabolic phenotyping","pmids":["34796475","33511118"],"confidence":"High","gaps":["How the same kinase produces pro- vs anti-inflammatory outcomes in different cell types is mechanistically incomplete","Interaction between endothelial and myeloid PRKAA1 in the same disease model not examined"]},{"year":null,"claim":"Outstanding questions include: the structural basis for α1 vs α2 isoform substrate specificity; how PRKAA1 integrates multiple upstream signals to produce context-dependent (protective vs pathological) outcomes in different tissues; and whether the tendon maintenance and neuronal memory functions represent conserved or tissue-specific AMPK signaling modules.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No crystal structure of full-length α1β1γ1 with physiological substrate bound","Isoform-specific interactomes not comprehensively mapped","Causal human genetic variants in PRKAA1 linked to Mendelian disease not yet reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,5,6,8,17]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,17]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,3,4,6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,6,7,15]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[8,10,21,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,14,17,22]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,6]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,1,2,5]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,19]}],"complexes":["AMPK (α1β1γ1 / α1β2γ1 heterotrimeric complex)"],"partners":["STK11","CAMKK2","RPTOR","TSC2","ULK1","BECN1","ACACA","TP53"],"other_free_text":[]},"mechanistic_narrative":"PRKAA1 encodes the catalytic α1 subunit of AMP-activated protein kinase (AMPK), a master energy sensor that coordinates cellular anabolism and catabolism in response to metabolic stress. Activated by phosphorylation at Thr-172 by LKB1 under energy stress or by CaMKKβ in response to Ca²⁺ signals [PMID:8910387, PMID:14985505, PMID:16054095], PRKAA1 directly phosphorylates substrates including ACC, TSC2, raptor, and ULK1 to inhibit mTORC1-driven growth, stimulate fatty acid oxidation, promote autophagy and mitophagy, and suppress ferroptosis [PMID:14651849, PMID:18439900, PMID:24988326, PMID:32029897]. These activities underpin diverse physiological roles: PRKAA1-dependent mitophagy is essential for erythrocyte maturation and prevention of hemolytic anemia [PMID:24988326]; endothelial PRKAA1 sustains protective glycolysis and vascular integrity against atherosclerosis [PMID:30405100]; myeloid PRKAA1 modulates macrophage inflammatory polarization by suppressing NF-κB and promoting anti-inflammatory cytokine production [PMID:19050283, PMID:33511118]; and muscle-specific PRKAA1 maintains lipid oxidative capacity and prevents intramyocellular lipid accumulation [PMID:29288408]. Loss of PRKAA1 in erythroid progenitors causes hemolytic anemia with splenomegaly due to failed mitochondrial clearance, a phenotype rescued by rapamycin [PMID:24988326]."},"prefetch_data":{"uniprot":{"accession":"Q13131","full_name":"5'-AMP-activated protein kinase catalytic subunit alpha-1","aliases":["Acetyl-CoA carboxylase kinase","ACACA kinase","Hydroxymethylglutaryl-CoA reductase kinase","HMGCR kinase","Tau-protein kinase PRKAA1"],"length_aa":559,"mass_kda":64.0,"function":"Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism (PubMed:17307971, PubMed:17712357, PubMed:24563466, PubMed:31492851, PubMed:37821951, PubMed:40233740). In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively (By similarity). Promotes lipolysis of lipid droplets by mediating phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757). Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3 (By similarity). AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160 (By similarity). Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A (PubMed:11518699, PubMed:11554766, PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By similarity). In response to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph), leading to promote transcription (By similarity). Acts as a key regulator of cell growth and proliferation by phosphorylating FNIP1, TSC2, RPTOR, WDR24 and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2 (PubMed:14651849, PubMed:18439900, PubMed:20160076, PubMed:21205641). Also phosphorylates and inhibits GATOR2 subunit WDR24 in response to nutrient limitation, leading to suppress glucose-mediated mTORC1 activation (PubMed:36732624). In response to energetic stress, phosphorylates FNIP1, inactivating the non-canonical mTORC1 signaling, thereby promoting nuclear translocation of TFEB and TFE3, and inducing transcription of lysosomal or autophagy genes (PubMed:37079666). In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1 (PubMed:21205641). In that process, it also activates WDR45/WIPI4 (PubMed:28561066). Phosphorylates CASP6, thereby preventing its autoprocessing and subsequent activation (PubMed:32029622). In response to nutrient limitation, phosphorylates transcription factor FOXO3 promoting FOXO3 mitochondrial import (By similarity). Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin (PubMed:17486097). AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it (By similarity). May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it (By similarity). Also has tau-protein kinase activity: in response to amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to phosphorylation of MAPT/TAU; however the relevance of such data remains unclear in vivo (By similarity). Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1 (PubMed:12519745, PubMed:20074060). Regulates hepatic lipogenesis. Activated via SIRT3, represses sterol regulatory element-binding protein (SREBP) transcriptional activities and ATP-consuming lipogenesis to restore cellular energy balance. Upon stress, regulates mitochondrial fragmentation through phosphorylation of MTFR1L (PubMed:36367943). Phosphorylates ALDH7A1 in response to cellular stress, such as hypoxia or ferroptotic stress, promoting ALDH7A1 recruitment to membranes (PubMed:31492851, PubMed:40233740)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13131/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKAA1","classification":"Not Classified","n_dependent_lines":14,"n_total_lines":1208,"dependency_fraction":0.011589403973509934},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000132356","cell_line_id":"CID001244","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"vesicles","grade":2},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"PRKAB2","stoichiometry":10.0},{"gene":"PRKAG1","stoichiometry":10.0},{"gene":"PRKAB1","stoichiometry":10.0},{"gene":"AKR1A1","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"SUB1","stoichiometry":0.2},{"gene":"PRKAR2A","stoichiometry":0.2},{"gene":"PRKAG2","stoichiometry":0.2},{"gene":"CLIP4","stoichiometry":0.2},{"gene":"INCENP","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001244","total_profiled":1310},"omim":[{"mim_id":"619308","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1E; PPM1E","url":"https://www.omim.org/entry/619308"},{"mim_id":"617471","title":"SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 12; SERPINA12","url":"https://www.omim.org/entry/617471"},{"mim_id":"615227","title":"COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 3; C1QL3","url":"https://www.omim.org/entry/615227"},{"mim_id":"613486","title":"MICRO RNA 33B; MIR33B","url":"https://www.omim.org/entry/613486"},{"mim_id":"612156","title":"MICRO RNA 33A; MIR33A","url":"https://www.omim.org/entry/612156"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRKAA1"},"hgnc":{"alias_symbol":["AMPKa1"],"prev_symbol":[]},"alphafold":{"accession":"Q13131","domains":[{"cath_id":"3.30.200.20","chopping":"21-106","consensus_level":"medium","plddt":86.8402,"start":21,"end":106},{"cath_id":"1.10.510.10","chopping":"108-286","consensus_level":"medium","plddt":94.682,"start":108,"end":286},{"cath_id":"1.10.8.10","chopping":"291-350","consensus_level":"high","plddt":73.4175,"start":291,"end":350},{"cath_id":"3.30.310.80","chopping":"410-478_540-557","consensus_level":"high","plddt":95.1575,"start":410,"end":557}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13131","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13131-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13131-F1-predicted_aligned_error_v6.png","plddt_mean":79.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKAA1","jax_strain_url":"https://www.jax.org/strain/search?query=PRKAA1"},"sequence":{"accession":"Q13131","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13131.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13131/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13131"}},"corpus_meta":[{"pmid":"25483961","id":"PMC_25483961","title":"Autophagy is not required to sustain exercise and PRKAA1/AMPK activity but is important to prevent mitochondrial damage during physical activity.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25483961","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30405100","id":"PMC_30405100","title":"PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30405100","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25225183","id":"PMC_25225183","title":"Maternal PRKAA1 and EDNRA genotypes are associated with birth weight, and PRKAA1 with uterine artery diameter and metabolic homeostasis at high altitude.","date":"2014","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25225183","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26029847","id":"PMC_26029847","title":"The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26029847","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24895169","id":"PMC_24895169","title":"Gene of the month. AMP kinase (PRKAA1).","date":"2014","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24895169","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29156518","id":"PMC_29156518","title":"LINC00152/miR-139-5p regulates gastric cancer cell aerobic glycolysis by targeting PRKAA1.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29156518","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20876741","id":"PMC_20876741","title":"Cellular stress causes reversible, PRKAA1/2-, and proteasome-dependent ID2 protein loss in trophoblast stem cells.","date":"2010","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20876741","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16595147","id":"PMC_16595147","title":"Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer.","date":"2006","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16595147","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29786111","id":"PMC_29786111","title":"High glucose suppresses the viability and proliferation of HTR‑8/SVneo cells through regulation of the miR‑137/PRKAA1/IL‑6 axis.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29786111","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24988326","id":"PMC_24988326","title":"PRKAA1/AMPKα1 is required for autophagy-dependent mitochondrial clearance during erythrocyte maturation.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/24988326","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20422711","id":"PMC_20422711","title":"Benzo(a)pyrene causes PRKAA1/2-dependent ID2 loss in trophoblast stem cells.","date":"2010","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/20422711","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23861218","id":"PMC_23861218","title":"Genetic variations in the PRKAA1 and ZBTB20 genes and gastric cancer susceptibility in a Korean population.","date":"2013","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23861218","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28814760","id":"PMC_28814760","title":"miR-181a involves in the hippocampus-dependent memory formation via targeting PRKAA1.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28814760","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31584290","id":"PMC_31584290","title":"LINC00473/miR-497-5p Regulates Esophageal Squamous Cell Carcinoma Progression Through Targeting PRKAA1.","date":"2019","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31584290","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30574617","id":"PMC_30574617","title":"TLR1 and PRKAA1 Gene Polymorphisms in the Development of Atrophic Gastritis and Gastric Cancer.","date":"2018","source":"Journal of gastrointestinal and liver diseases : JGLD","url":"https://pubmed.ncbi.nlm.nih.gov/30574617","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35435532","id":"PMC_35435532","title":"Inhibition of miR-130b-3p restores autophagy and attenuates intervertebral disc degeneration through mediating ATG14 and PRKAA1.","date":"2022","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/35435532","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31558185","id":"PMC_31558185","title":"PRKAA1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells Through Activating JNK1 and Akt Pathways.","date":"2019","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/31558185","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36305690","id":"PMC_36305690","title":"PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.","date":"2022","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/36305690","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36906969","id":"PMC_36906969","title":"Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36906969","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25024613","id":"PMC_25024613","title":"Risk of gastric cancer is associated with PRKAA1 gene polymorphisms in Koreans.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25024613","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36924562","id":"PMC_36924562","title":"PRKAA1 induces aberrant mitophagy in a PINK1/Parkin-dependent manner, contributing to fluoride-induced developmental neurotoxicity.","date":"2023","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/36924562","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34659329","id":"PMC_34659329","title":"CircC6orf132 Facilitates Proliferation, Migration, Invasion, and Glycolysis of Gastric Cancer Cells Under Hypoxia by Acting on the miR-873-5p/PRKAA1 Axis.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34659329","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29288408","id":"PMC_29288408","title":"Muscle-specific deletion of Prkaa1 enhances skeletal muscle lipid accumulation in mice fed a high-fat diet.","date":"2017","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29288408","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33302416","id":"PMC_33302416","title":"Expression and Impact of Vaspin on In Vitro Oocyte Maturation through MAP3/1 and PRKAA1 Signalling Pathways.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33302416","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31841039","id":"PMC_31841039","title":"Involvement of NF-κB signaling pathway in the regulation of PRKAA1-mediated tumorigenesis in gastric cancer.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31841039","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34796475","id":"PMC_34796475","title":"Endothelial AMPKα1/PRKAA1 exacerbates inflammation in HFD-fed mice.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34796475","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20686348","id":"PMC_20686348","title":"siRNA-mediated AMPKalpha1 subunit gene PRKAA1 silencing enhances methylmercury toxicity in HEK293 cells.","date":"2010","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20686348","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27726301","id":"PMC_27726301","title":"Additive interactions between PRKAA1 polymorphisms and Helicobacter pylori CagA infection associated with gastric cancer risk in Koreans.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27726301","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33511118","id":"PMC_33511118","title":"Prkaa1 Metabolically Regulates Monocyte/Macrophage Recruitment and Viability in Diet-Induced Murine Metabolic Disorders.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33511118","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29620653","id":"PMC_29620653","title":"Association between PRKAA1 rs13361707 T>C polymorphism and gastric cancer risk: Evidence based on a meta-analysis.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29620653","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37670284","id":"PMC_37670284","title":"Association of PTGER4 and PRKAA1 genetic polymorphisms with gastric cancer.","date":"2023","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37670284","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35297212","id":"PMC_35297212","title":"Circ_0003340 downregulation mitigates esophageal squamous cell carcinoma progression by targeting miR-940/PRKAA1 axis.","date":"2022","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35297212","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30253744","id":"PMC_30253744","title":"Genetic variations in PRKAA1 predict the risk and progression of gastric Cancer.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30253744","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40395536","id":"PMC_40395536","title":"Gentiacaulein inhibits glucose transport to induce PRKAA1-mediated autophagy to clear amyloid beta and associated inflammation in primary astrocytes.","date":"2024","source":"Autophagy reports","url":"https://pubmed.ncbi.nlm.nih.gov/40395536","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36818655","id":"PMC_36818655","title":"Genetic polymorphisms of PRKAA1 (AMPKα1) and postherpetic pain susceptibility: Multicenter, randomized control, and haplotype analysis study.","date":"2023","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36818655","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27612659","id":"PMC_27612659","title":"Association of PRKAA1 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.","date":"2016","source":"The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27612659","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32488984","id":"PMC_32488984","title":"PRKAA1 rs13361707 C/T polymorphism confers decreased susceptibility to esophageal cancer: A case-control study.","date":"2020","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/32488984","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40703441","id":"PMC_40703441","title":"Adaptive PRKAA1 variant in Andeans is associated with improved ventilation and sleep phenotypes.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40703441","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38878971","id":"PMC_38878971","title":"miR-181a expressed in the dorsal hippocampus regulates the reinstatement of cocaine CPP by targeting PRKAA1.","date":"2024","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/38878971","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.18.665488","title":"Coffee consumption affects adipose tissue remodeling in a high-fat diet-induced obesity model by different mechanisms in rats","date":"2025-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.18.665488","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.31.635920","title":"AMP-activated protein kinase (AMPK) is essential for tendon homeostasis and prevents premature senescence and ectopic calcification","date":"2025-02-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.31.635920","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.05.07.592914","title":"Daily Acute Intermittent Hypoxia Elicits Age & Sex-Dependent Changes in Molecules Regulating Phrenic Motor Plasticity","date":"2024-05-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.07.592914","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12368907","id":"PMC_12368907","title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12368907","citation_count":3297,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14651849","id":"PMC_14651849","title":"TSC2 mediates cellular energy response to control cell growth and survival.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/14651849","citation_count":3187,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18439900","id":"PMC_18439900","title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18439900","citation_count":3139,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21892142","id":"PMC_21892142","title":"The AMPK signalling pathway coordinates cell growth, autophagy and metabolism.","date":"2011","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21892142","citation_count":2435,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16054041","id":"PMC_16054041","title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.","date":"2005","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16054041","citation_count":2232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14985505","id":"PMC_14985505","title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14985505","citation_count":1500,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15866171","id":"PMC_15866171","title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15866171","citation_count":1363,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16054095","id":"PMC_16054095","title":"Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase.","date":"2005","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16054095","citation_count":1350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20562859","id":"PMC_20562859","title":"Network organization of the human autophagy system.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20562859","citation_count":1286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14976552","id":"PMC_14976552","title":"LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14976552","citation_count":1153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8910387","id":"PMC_8910387","title":"Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8910387","citation_count":1041,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12906785","id":"PMC_12906785","title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/12906785","citation_count":983,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18674809","id":"PMC_18674809","title":"AMPK and PPARdelta agonists are exercise mimetics.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18674809","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32029897","id":"PMC_32029897","title":"Energy-stress-mediated AMPK activation inhibits ferroptosis.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32029897","citation_count":928,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27416781","id":"PMC_27416781","title":"Regulation and function of AMPK in physiology and diseases.","date":"2016","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27416781","citation_count":888,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15261145","id":"PMC_15261145","title":"The LKB1 tumor suppressor negatively regulates mTOR signaling.","date":"2004","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15261145","citation_count":883,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28386764","id":"PMC_28386764","title":"Roles of tau protein in health and disease.","date":"2017","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/28386764","citation_count":716,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11997383","id":"PMC_11997383","title":"AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11997383","citation_count":687,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19050283","id":"PMC_19050283","title":"Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19050283","citation_count":645,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24529379","id":"PMC_24529379","title":"Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/24529379","citation_count":645,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24000,"output_tokens":4311,"usd":0.068333},"stage2":{"model":"claude-opus-4-6","input_tokens":7805,"output_tokens":2776,"usd":0.162637},"total_usd":0.567482,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":35936,"output_tokens":6919,"usd":0.105797},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10572,"output_tokens":4038,"usd":0.230715}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"PRKAA1/AMPKα1 is required for autophagy-dependent mitochondrial clearance during erythrocyte maturation: deletion of Prkaa1 inhibits ULK1 phosphorylation at Ser555, prevents formation of ULK1-BECN1-PtdIns3K complexes, reduces autophagic flux, and leads to damaged mitochondrial accumulation, ROS production, hemolytic anemia, and splenomegaly.\",\n      \"method\": \"Prkaa1 knockout mice, bone marrow transplantation, ULK1 phosphorylation assay, autophagic flux measurement, mitochondrial ROS quantification, rapamycin and mitochondria-targeted antioxidant rescue\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, multiple orthogonal rescue approaches, reciprocal bone marrow transplants confirming cell-autonomous mechanism\",\n      \"pmids\": [\"24988326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Autophagy is not required to sustain exercise-induced PRKAA1 activation or glucose homeostasis, but PRKAA1-dependent autophagy is critical for mitochondrial quality control during damaging muscle contraction.\",\n      \"method\": \"Inducible muscle-specific Atg7 knockout mice, exercise performance testing, PRKAA1 activation assay, mitochondrial function assessment during contraction\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean inducible muscle-specific KO with defined phenotypic readout and functional rescue context\",\n      \"pmids\": [\"25483961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CAMKK2-PRKAA1-ULK1 signaling pathway is required for CSF1-induced autophagy and human monocyte-to-macrophage differentiation; PRKAA1 links P2RY6 receptor signaling to autophagy induction.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibitors, autophagy flux assays in primary human monocytes and cell lines, pathway epistasis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established through genetic and pharmacological inhibition at multiple nodes, replicated in primary human cells\",\n      \"pmids\": [\"26029847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Endothelial PRKAA1 drives aerobic glycolysis to promote endothelial cell proliferation and barrier integrity in atheroprone vascular regions; endothelial-specific Prkaa1 deletion reduces glycolysis and accelerates atherosclerotic lesion formation, which is rescued by GLUT1 (SLC2A1) overexpression.\",\n      \"method\": \"Endothelial-specific Prkaa1 knockout mice in hyperlipidemic background, atherosclerosis quantification, glycolysis measurement (ECAR), Slc2a1 overexpression rescue, siRNA in human endothelial cells\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-type-specific KO with defined molecular and phenotypic readout, genetic rescue experiment, replicated in human cells\",\n      \"pmids\": [\"30405100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PRKAA1/2 (AMPK) mediates stress-induced, proteasome-dependent loss of ID2 protein in trophoblast stem cells, linking cellular stress to differentiation; at low stress levels, PRKAA1/2 mediates metabolic adaptation (acetyl-CoA carboxylase phosphorylation) without ID2 loss.\",\n      \"method\": \"AMPK inhibitor compound C, proteasome inhibitors, ID2 protein quantification, acetyl-CoA carboxylase phosphorylation assay in mouse TSCs\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with defined molecular readout, but no genetic KO confirmation\",\n      \"pmids\": [\"20876741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Benzo(a)pyrene (BaP) activates PRKAA1/2 and causes PRKAA1/2-dependent loss of ID2 protein in trophoblast stem cells at doses that reduce TSC accumulation and proliferation.\",\n      \"method\": \"BaP treatment of mouse TSCs, AMPK activation assay, ID2 protein quantification, cell accumulation assay\",\n      \"journal\": \"Molecular Reproduction and Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological activation with defined molecular readout in cell model, single lab\",\n      \"pmids\": [\"20422711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Muscle-specific deletion of Prkaa1 enhances skeletal muscle lipid accumulation on a high-fat diet, activates mTOR signaling, upregulates adipogenic genes, and downregulates mitochondrial oxidation genes, establishing PRKAA1 as a regulator of intramyocellular lipid metabolism.\",\n      \"method\": \"Muscle-specific Prkaa1 knockout mice, high-fat diet challenge, IMTG quantification, gene expression profiling, mTOR pathway Western blotting\",\n      \"journal\": \"Journal of Physiology and Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean tissue-specific KO with defined metabolic phenotype, but single lab\",\n      \"pmids\": [\"29288408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Endothelial PRKAA1 promotes inflammatory gene transcription in a high-fat diet context by maintaining glycolysis and fatty acid oxidation, increasing acetyl-CoA levels, and supporting ATP citrate lyase/histone acetyltransferase p300-mediated histone acetylation at inflammatory gene loci.\",\n      \"method\": \"EC-specific Prkaa1 KO mice on HFD, acetyl-CoA quantification, ATP citrate lyase and p300 inhibitor experiments, metabolic flux assays, flow cytometry for tissue inflammation\",\n      \"journal\": \"British Journal of Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with defined mechanistic pathway (acetyl-CoA → p300 → inflammatory transcription), single lab\",\n      \"pmids\": [\"34796475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Prkaa1 deficiency in myeloid cells downregulates glucose and lipid metabolic genes, impairs macrophage recruitment to adipose tissue, liver, and arterial wall, and reduces macrophage viability, thereby attenuating diet-induced metabolic syndrome and atherosclerosis.\",\n      \"method\": \"Myeloid-specific Prkaa1 KO mice on HFD/Western diet, metabolic phenotyping, flow cytometry for tissue macrophage content, gene expression analysis\",\n      \"journal\": \"Frontiers in Cell and Developmental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-type-specific KO with defined cellular and metabolic phenotype, single lab\",\n      \"pmids\": [\"33511118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRKAA1 promotes gastric cancer cell proliferation and inhibits apoptosis through activation of JNK1 and Akt signaling pathways; shRNA knockdown of PRKAA1 reduces PCNA and Bcl-2 expression and inhibits JNK1 and Akt activity.\",\n      \"method\": \"shRNA knockdown, AMPK inhibitor compound C, JNK1/Akt pathway inhibitors, proliferation and apoptosis assays, xenograft mouse model\",\n      \"journal\": \"Oncology Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway readout and in vivo validation, single lab\",\n      \"pmids\": [\"31558185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRKAA1 induces aberrant PINK1/Parkin-dependent mitophagy in response to fluoride (NaF) exposure, contributing to neuronal apoptosis; PRKAA1 phosphorylation is enhanced by NaF and its inhibition restores normal mitophagy and reduces apoptosis.\",\n      \"method\": \"NaF-treated SH-SY5Y cells and rat model, phosphoproteomics, AMPK inhibitor dorsomorphin, autophagy inhibitor 3-MA, Western blotting for PINK1/Parkin/TOMM20/Cyt C\",\n      \"journal\": \"Ecotoxicology and Environmental Safety\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition in both in vitro and in vivo models with defined PINK1/Parkin pathway readout, single lab\",\n      \"pmids\": [\"36924562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO stabilizes PRKAA1 mRNA by reducing m6A modification in an m6A-YTHDF2-dependent manner; increased m6A on PRKAA1 3'-UTR promotes its degradation by YTHDF2, while FTO demethylase activity removes m6A to increase PRKAA1 protein levels in gastric cancer cells.\",\n      \"method\": \"RNA immunoprecipitation (m6A-RIP), YTHDF2 binding assay, FTO knockdown/overexpression, PRKAA1 mRNA stability assay, Western blotting\",\n      \"journal\": \"Neoplasma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — m6A-RIP and protein interaction assay with functional readout, single lab\",\n      \"pmids\": [\"36305690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-139-5p inhibits glycolysis in gastric cancer cells by directly targeting and downregulating PRKAA1; LINC00152 sponges miR-139-5p to sustain PRKAA1 expression and aerobic glycolysis.\",\n      \"method\": \"Luciferase reporter assay, miRNA overexpression/inhibition, glycolysis assays, Western blotting for PRKAA1\",\n      \"journal\": \"Biomedicine & Pharmacotherapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, luciferase reporter with functional glycolysis readout but limited mechanistic depth\",\n      \"pmids\": [\"29156518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NF-κBp50 transcriptionally regulates PRKAA1 expression in gastric cancer; H. pylori infection increases NF-κBp50 and PRKAA1 expression, and PRKAA1 in turn activates NF-κB signaling to promote MMP-2 expression, cell invasion, and migration.\",\n      \"method\": \"NF-κBp50 siRNA knockdown, PRKAA1 knockdown, H. pylori infection model, invasion/migration assays, MMP-2 Western blotting, xenograft metastasis model\",\n      \"journal\": \"Artificial Cells, Nanomedicine, and Biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological and siRNA approach with defined downstream pathway, but limited mechanistic validation\",\n      \"pmids\": [\"31841039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Gentiacaulein inhibits glucose transport, raises the AMP:ATP ratio, and activates PRKAA1-mediated autophagy in astrocytes, enhancing amyloid-β clearance and reducing NF-κB nuclear translocation and inflammatory cytokine release; PRKAA1 knockdown reverses these effects.\",\n      \"method\": \"PRKAA1 siRNA knockdown, AMP/ATP ratio measurement, autophagic flux assays, NF-κB translocation assay, amyloid-β clearance quantification, cytokine ELISA in primary astrocytes\",\n      \"journal\": \"Autophagy Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA rescue experiment with multiple orthogonal readouts in primary cells, single lab\",\n      \"pmids\": [\"40395536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-181a in the dorsal hippocampus targets PRKAA1 to regulate hippocampus-dependent memory formation; after fear conditioning or object location training, miR-181a increases and PRKAA1 activity decreases, and microinjection of PRKAA1 agonist AICAR or inhibitor compound C reverses miR-181a-induced memory effects.\",\n      \"method\": \"Luciferase reporter assay, stereotaxic miR-181a agomir/antagomir injection, PRKAA1 activity measurement, AICAR/compound C microinjection, behavioral memory tests\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — validated miRNA target interaction with in vivo pharmacological rescue in defined brain region, single lab\",\n      \"pmids\": [\"28814760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"miR-181a in the dorsal hippocampus targets PRKAA1 to regulate reinstatement of cocaine conditioned place preference; high miR-181a reduces PRKAA1 mRNA, activates mTOR signaling, alters dendritic spine morphology, and promotes cocaine CPP reinstatement.\",\n      \"method\": \"Luciferase reporter assay, miR-181a agomir/antagomir injection, PRKAA1 and mTOR Western blotting, dendritic spine morphology analysis, behavioral CPP assay\",\n      \"journal\": \"Behavioural Brain Research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, luciferase reporter plus behavioral readout, limited direct PRKAA1 mechanistic validation\",\n      \"pmids\": [\"38878971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"siRNA-mediated silencing of PRKAA1 increases susceptibility of HEK293 cells to methylmercury toxicity, while AICAR-mediated AMPK activation reduces toxicity, establishing PRKAA1/AMPK activation as a cellular defense mechanism against methylmercury.\",\n      \"method\": \"siRNA knockdown, AICAR pharmacological activation, cell viability assays in HEK293 cells\",\n      \"journal\": \"Journal of Toxicological Sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological and siRNA approach with cell viability readout, no downstream mechanistic detail\",\n      \"pmids\": [\"20686348\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKAA1 encodes the catalytic α1 subunit of AMPK, functioning as a cellular energy sensor that, when activated by elevated AMP:ATP ratios, phosphorylates ULK1 (Ser555) to induce autophagy and mitophagy (via PINK1/Parkin), suppresses anabolic pathways, drives endothelial glycolysis and macrophage metabolism, regulates trophoblast stem cell differentiation through proteasomal ID2 degradation, and modulates inflammatory gene transcription through an acetyl-CoA/p300 histone acetyltransferase axis, while its own expression is post-transcriptionally regulated by FTO-mediated m6A demethylation and multiple miRNAs (miR-139-5p, miR-181a, miR-497-5p, miR-873-5p).\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify papers before extracting discoveries.\n\n**Classification notes:**\n- Paper 42 (preprint on daily AIH): mentions \"Prkaa1\" as \"PKA catalytic subunit\" — this is a SYMBOL COLLISION where Prkaa1 is being used to mean PKA (protein kinase A) catalytic subunit, not AMPK. EXCLUDE.\n- Paper 40 (coffee/adipose preprint): mentions Prkaa1/Prkaa2 mRNA levels in eWAT — this is expression/correlation data only, no mechanism. EXCLUDE (pure expression).\n- Papers on GWAS/SNP associations (3, 12, 15, 20, 28, 30, 31, 33, 35, 36, 37): expression/association studies only. EXCLUDE.\n- Papers from gene2pubmed that are general AMPK/interactome papers without specific PRKAA1 mechanistic findings need careful review.\n- Paper 42 from curated list (preprint bio_10.1101_2025.01.31.635920): specifically about Prkaa1 deletion in tendon. KEEP.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The upstream kinase (later identified as LKB1) phosphorylates the AMPK alpha subunit (PRKAA1) at a single major site, threonine 172, located in the activation segment between the DFG and APE motifs; this phosphorylation is absolutely required for AMP-dependent activation and is antagonized by high ATP concentrations.\",\n      \"method\": \"In vitro kinase assay with purified rat liver AMPK kinase cascade; site identification by phosphopeptide mapping and mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified enzymes, site-directed identification, replicated extensively\",\n      \"pmids\": [\"8910387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LKB1 serine/threonine kinase directly phosphorylates Thr-172 on the AMPK alpha subunit (PRKAA1) in vitro and in cells, serving as the dominant upstream activating kinase; LKB1-deficient cells show near-complete loss of Thr-172 phosphorylation and are hypersensitive to energy-stress-induced apoptosis.\",\n      \"method\": \"In vitro kinase assay; LKB1-knockout MEFs; reintroduction of WT vs kinase-dead LKB1; cell death assay under energy stress\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation plus genetic rescue in LKB1-null cells, replicated across labs\",\n      \"pmids\": [\"14985505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CaMKKβ (calmodulin-dependent protein kinase kinase beta) is an alternative upstream kinase that phosphorylates and activates AMPK (PRKAA1) in a Ca2+-dependent, AMP-independent manner in LKB1-deficient cells; this represents a Ca2+-dependent neuroprotective pathway.\",\n      \"method\": \"CaMKK inhibitor STO-609; isoform-specific siRNA knockdown; Ca2+ ionophore stimulation in LKB1-null cells; cell-free kinase assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assay plus genetic (siRNA) dissection in intact cells, replicated\",\n      \"pmids\": [\"16054095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Adiponectin activates AMPK (including the alpha1/PRKAA1 subunit) in skeletal muscle and liver, stimulating phosphorylation of acetyl-CoA carboxylase, fatty-acid oxidation, and glucose uptake; dominant-negative AMPK blocks each of these effects, placing PRKAA1 downstream of adiponectin and upstream of ACC and fatty acid oxidation.\",\n      \"method\": \"Dominant-negative AMPK transfection; in vitro AMPK activity assay; ACC phosphorylation; fatty acid oxidation assay in myocytes; glucose uptake measurement\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays with dominant-negative epistasis, replicated\",\n      \"pmids\": [\"12368907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"AMPK (PRKAA1) phosphorylates TSC2 under energy starvation, enhancing TSC2 activity to suppress mTOR-dependent translation and cell growth; TSC2 phosphorylation by AMPK is required for cell-size control and protection from energy-deprivation-induced apoptosis.\",\n      \"method\": \"In vitro AMPK kinase assay on TSC2; genetic epistasis with TSC2-null cells; cell size measurement; apoptosis assay under energy stress\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in vitro phosphorylation plus genetic epistasis, independently replicated\",\n      \"pmids\": [\"14651849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"AMPK activation (involving PRKAA1) induces phosphorylation of p53 on serine 15, triggering a G1/S cell-cycle checkpoint in response to glucose deprivation; this AMPK-p53 axis promotes cellular survival during energy stress but drives senescence upon persistent activation.\",\n      \"method\": \"Pharmacological AMPK activation (AICAR); p53-S15 phosphorylation by immunoblot; cell-cycle analysis; p53-null cell epistasis; glucose deprivation survival assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pharmacological activation + genetic p53 epistasis + cell cycle), independently replicated\",\n      \"pmids\": [\"15866171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AMPK (PRKAA1) directly phosphorylates raptor on two conserved serine residues, inducing 14-3-3 binding to raptor; this phosphorylation is required for mTORC1 inhibition and cell-cycle arrest in response to energy stress, revealing raptor as a direct AMPK substrate mediating the metabolic checkpoint.\",\n      \"method\": \"Proteomic substrate screen; in vitro kinase assay with purified AMPK and raptor; 14-3-3 co-immunoprecipitation; raptor phospho-mutants; cell-cycle analysis in energy-stressed cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation, mutagenesis, Co-IP, and functional epistasis in one study\",\n      \"pmids\": [\"18439900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AMPK alpha1 (PRKAA1) in macrophages suppresses LPS-induced proinflammatory cytokine production (TNF-α, IL-6) and promotes IL-10; dominant-negative AMPKα1 enhances inflammatory responses while constitutively active AMPKα1 reduces them; AMPK negatively regulates IκB-α degradation and positively regulates Akt/CREB signaling.\",\n      \"method\": \"siRNA knockdown; dominant-negative and constitutively active AMPKα1 transfection in macrophages; cytokine ELISA; IκB-α and Akt phosphorylation by immunoblot\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with multiple downstream readouts in same cell type\",\n      \"pmids\": [\"19050283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PRKAA1 is required for ULK1 phosphorylation at Ser555 and formation of ULK1-BECN1-PtdIns3K complexes necessary for autophagy-dependent mitochondrial clearance (mitophagy) during erythrocyte maturation; prkaa1−/− mice develop hemolytic anemia, splenomegaly, and shortened erythrocyte lifespan due to accumulation of damaged mitochondria and elevated ROS, all rescued by rapamycin or mitochondria-targeted antioxidant treatment.\",\n      \"method\": \"prkaa1 knockout mice; bone marrow transplantation; ULK1 Ser555 phosphorylation immunoblot; Co-IP of ULK1-BECN1 complex; autophagic flux assay; mitochondrial content and ROS measurement; hematologic parameters\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with bone marrow transplant rescue, multiple orthogonal mechanistic readouts\",\n      \"pmids\": [\"24988326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Autophagy is not required for exercise performance or PRKAA1 activation during physical activity, but autophagy (requiring PRKAA1-dependent signaling) is critical for mitochondrial quality control during damaging muscle contraction; this protective effect is gender-specific, primarily affecting females.\",\n      \"method\": \"Inducible muscle-specific Atg7 knockout mice; treadmill exercise testing; PRKAA1 activity assay; glucose homeostasis measurement; mitochondrial function assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean inducible KO with defined phenotype, but single lab\",\n      \"pmids\": [\"25483961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CAMKK2-PRKAA1-ULK1 signaling pathway is required for CSF1-induced autophagy and human monocyte-to-macrophage differentiation; PRKAA1 links P2RY6 receptor engagement to autophagy induction, and pharmacological P2RY6 agonists can restore autophagy and normal differentiation in CMML patient cells.\",\n      \"method\": \"siRNA knockdown of CAMKK2, PRKAA1, ULK1 in human monocytes; autophagy flux assay; differentiation markers; P2RY6 agonist treatment; primary CMML patient cells\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistatic pathway dissection with multiple siRNA knockdowns plus patient validation\",\n      \"pmids\": [\"26029847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PRKAA1/2 mediates stress-induced proteasome-dependent loss of ID2 protein in trophoblast stem cells; at low stress levels, PRKAA1/2 mediates metabolic adaptation (ACC inactivation by phosphorylation) without ID2 loss, while higher stress drives irreversible TSC differentiation via ID2 loss.\",\n      \"method\": \"AMPK inhibitor compound C; PRKAA1/2 siRNA; proteasome inhibitor; ID2 immunoblot; ACC phosphorylation assay; cell accumulation assay in mouse TSCs\",\n      \"journal\": \"Reproduction (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological and siRNA approaches with defined molecular and phenotypic readouts, single lab\",\n      \"pmids\": [\"20876741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Benzo(a)pyrene (BaP) activates PRKAA1/2 and causes PRKAA1/2-dependent loss of ID2 protein in trophoblast stem cells in a dose-dependent manner; this occurs at BaP doses equivalent to approximately 2-3 pack/day smoking, suggesting a mechanism for implantation failure in smokers.\",\n      \"method\": \"AMPK activity assay; PRKAA1/2 siRNA in mouse TSCs; ID2 immunoblot; BaP dose-response; cell proliferation measurement\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — siRNA plus pharmacological with defined molecular readout, single lab\",\n      \"pmids\": [\"20422711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"siRNA silencing of PRKAA1 (AMPKα1) in HEK293 cells increases susceptibility to methylmercury toxicity, while AICAR-mediated AMPK activation reduces toxicity, indicating that PRKAA1 phosphorylation/activation plays a protective role against methylmercury-induced cell death.\",\n      \"method\": \"siRNA knockdown of PRKAA1; AICAR pharmacological activation; cell viability assay after methylmercury treatment\",\n      \"journal\": \"The Journal of toxicological sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single method (siRNA + pharmacological), no downstream mechanism defined\",\n      \"pmids\": [\"20686348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Selective endothelial deletion of Prkaa1 reduces glycolysis, compromises endothelial cell proliferation, and accelerates atherosclerotic lesion formation in hyperlipidemic mice; rescue of glycolysis via Slc2a1 (GLUT1) overexpression restores endothelial viability, barrier integrity, and reverses atherosclerosis susceptibility, placing PRKAA1-driven glycolysis upstream of endothelial protection.\",\n      \"method\": \"Endothelial-specific Prkaa1 knockout mice; atherosclerosis lesion quantification; Slc2a1 overexpression rescue; glycolysis measurement (ECAR); endothelial barrier assay; human EC siRNA knockdown\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO, genetic rescue, multiple phenotypic readouts across mouse and human cells\",\n      \"pmids\": [\"30405100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRKAA1 promotes gastric cancer cell proliferation and inhibits apoptosis through activation of JNK1 and Akt signaling pathways; pharmacological inhibition (compound C) or shRNA knockdown of PRKAA1 reduces PCNA and Bcl-2 expression and blocks JNK1/Akt activity; inactivation of JNK1 or Akt reverses PRKAA1 overexpression-induced proliferation.\",\n      \"method\": \"shRNA knockdown; AMPK inhibitor compound C; JNK1/Akt inhibitors; PCNA/Bcl-2 immunoblot; xenograft tumor growth assay in nude mice\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic and pharmacological approaches with pathway inhibitor epistasis, single lab\",\n      \"pmids\": [\"31558185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NF-κBp50 transcriptionally regulates PRKAA1 expression in response to H. pylori infection; PRKAA1 in turn activates NF-κB signaling and promotes MMP-2 expression, gastric cancer cell invasion and migration; knockdown of PRKAA1 reduces metastasis in nude mice.\",\n      \"method\": \"NF-κBp50 siRNA; PRKAA1 stable shRNA knockdown; MMP-2 immunoblot; invasion/migration assay; lung metastasis xenograft model\",\n      \"journal\": \"Artificial cells, nanomedicine, and biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epistatic knockdown of NF-κB upstream and PRKAA1 downstream with in vivo validation, single lab\",\n      \"pmids\": [\"31841039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Energy stress activates AMPK (PRKAA1), which inhibits ferroptosis partly through AMPK-mediated phosphorylation of acetyl-CoA carboxylase (ACC) and consequent reduction of polyunsaturated fatty acid biosynthesis; AMPK inactivation abolishes the protective effects of energy stress on ferroptosis in vitro and in renal ischemia-reperfusion injury in vivo.\",\n      \"method\": \"AMPK genetic inactivation; energy-stress treatments; ferroptosis assay; lipidomic analysis; ACC phosphorylation; renal IRI mouse model\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic AMPK inactivation with lipidomic mechanistic validation and in vivo model\",\n      \"pmids\": [\"32029897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Endothelial PRKAA1 deficiency in HFD-fed mice unexpectedly alleviates metabolic syndrome; mechanistically, PRKAA1 knockdown in ECs reduces glycolysis and fatty acid oxidation, decreases acetyl-CoA levels, and suppresses inflammatory gene transcription mediated by ATP citrate lyase and histone acetyltransferase p300.\",\n      \"method\": \"EC-specific Prkaa1 knockout mice on HFD; metabolic phenotyping; EC glycolysis/FAO measurement; acetyl-CoA quantification; p300 histone acetyltransferase activity; inflammatory gene expression\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with mechanistic dissection through acetyl-CoA/p300 pathway\",\n      \"pmids\": [\"34796475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Myeloid-specific Prkaa1 deficiency downregulates glucose and lipid metabolism genes in macrophages, impairs their metabolic fitness, and suppresses monocyte/macrophage recruitment to adipose tissue, liver, and arterial walls, reducing atherosclerosis, adipose inflammation, and HFD-induced metabolic disorders.\",\n      \"method\": \"Myeloid-specific Prkaa1 knockout mice; metabolic gene expression; macrophage glucose/lipid metabolism assays; flow cytometry of tissue macrophages; atherosclerosis lesion quantification\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with metabolic and cellular phenotype, single lab\",\n      \"pmids\": [\"33511118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO demethylase stabilizes PRKAA1 mRNA by reducing m6A modification at the 3'-UTR, preventing YTHDF2-mediated degradation; increased PRKAA1 protein promotes gastric cancer cell growth and glycolysis while suppressing apoptosis by regulating the redox balance (GSH, NADPH levels).\",\n      \"method\": \"RNA immunoprecipitation (m6A-RIP); YTHDF2 interaction assay with PRKAA1 3'-UTR; FTO siRNA/overexpression; PRKAA1 silencing/overexpression; lactic acid, GSH, NADP+/NADPH measurement; ECAR analysis\",\n      \"journal\": \"Neoplasma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — m6A-RIP and RIP mechanistic experiments, single lab\",\n      \"pmids\": [\"36305690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRKAA1 activation induces aberrant PINK1/Parkin-dependent mitophagy in fluoride-exposed neurons; sodium fluoride increases PRKAA1 phosphorylation and upregulates PINK1, Parkin, TOMM20, and Cyt C; both AMPK inhibitor (dorsomorphin) and autophagy inhibitor (3-MA) rescue NaF-induced neuronal apoptosis by restoring normal mitophagic flux.\",\n      \"method\": \"NaF-treated SH-SY5Y cells and rat model; phosphoproteomics; PINK1/Parkin/TOMM20 immunoblot; autophagic flux assay; dorsomorphin and 3-MA pharmacological rescue; apoptosis assay\",\n      \"journal\": \"Ecotoxicology and environmental safety\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — phosphoproteomic identification plus pharmacological epistasis in vitro and in vivo, single lab\",\n      \"pmids\": [\"36924562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Muscle-specific deletion of Prkaa1 delays skeletal muscle development and, under high-fat diet, leads to enhanced intramyocellular lipid accumulation with upregulation of adipogenic genes and downregulation of mitochondrial oxidation genes; Prkaa1 deletion also activates skeletal muscle mTOR signaling, which contributes to impaired lipid metabolism.\",\n      \"method\": \"Muscle-specific Prkaa1 knockout mice; HFD feeding; intramyocellular triglyceride quantification; adipogenic and mitochondrial gene expression; mTOR pathway immunoblot; glucose tolerance and insulin sensitivity tests\",\n      \"journal\": \"Journal of physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with defined metabolic phenotype and pathway analysis, single lab\",\n      \"pmids\": [\"29288408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GENT (gentiacaulein) inhibits glucose transport, raising the AMP:ATP ratio and activating PRKAA1-mediated autophagy in astrocytes; increased PRKAA1-dependent autophagy enhances clearance of amyloid-β; PRKAA1 knockdown reverses GENT-induced autophagy and anti-inflammatory effects, confirming PRKAA1 as the mechanistic link between energy sensing and Aβ clearance.\",\n      \"method\": \"Pharmacological glucose transport inhibition; AMP:ATP ratio measurement; PRKAA1 siRNA knockdown; autophagy flux assay; Aβ clearance quantification; NF-κB nuclear translocation assay; cytokine measurement\",\n      \"journal\": \"Autophagy reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — siRNA epistasis with multiple downstream readouts, single lab\",\n      \"pmids\": [\"40395536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Selective deletion of Prkaa1 in tendon progenitors causes normal postnatal development but progressive tendon pathology: by one month, widespread transcriptional changes in cell cycle regulation and ECM organization appear; by three months, AMPKα1-deficient tendons show reduced mechanical strength, elevated senescence markers (p21, p16), and eventual ectopic calcification; in vitro, tendon fibroblasts lacking AMPKα1 have altered ECM substrate adhesion; voluntary exercise partially rescues these deficits by improving ECM organization and reducing senescence.\",\n      \"method\": \"Conditional Prkaa1 knockout in tendon progenitors; RNA sequencing; mechanical tensile testing; senescence marker immunostaining; ectopic calcification histology; ECM adhesion assay; voluntary exercise intervention\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with multiple phenotypic and transcriptomic readouts, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.01.31.635920\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-181a targets PRKAA1 in hippocampal neurons (validated by luciferase reporter assay); CFC/OLT training transiently increases miR-181a and decreases PRKAA1 expression/activity; microinjection of PRKAA1 agonist AICAR or inhibitor compound C in the dorsal hippocampus reverses the effects of miR-181a manipulation on memory formation, placing PRKAA1 downstream of miR-181a in hippocampus-dependent memory consolidation.\",\n      \"method\": \"Luciferase reporter assay; miR-181a agomir/antagomir injection; PRKAA1 activity measurement; AICAR/compound C hippocampal microinjection; fear conditioning and object location behavioral tests\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — luciferase validation plus pharmacological epistasis in vivo with behavioral readout, single lab\",\n      \"pmids\": [\"28814760\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKAA1 encodes the catalytic α1 subunit of AMPK, which is activated by phosphorylation at Thr-172 by upstream kinases LKB1 (energy-stress-dependent) or CaMKKβ (Ca2+-dependent); active PRKAA1 phosphorylates downstream substrates including TSC2, raptor, ACC, and ULK1 to coordinately inhibit mTORC1-driven anabolism, promote autophagy and mitophagy, suppress ferroptosis via ACC-mediated PUFA biosynthesis reduction, regulate macrophage inflammatory polarization, drive protective glycolysis in endothelial cells, maintain erythrocyte homeostasis, and sustain tendon and skeletal muscle metabolic integrity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRKAA1 encodes the catalytic α1 subunit of AMP-activated protein kinase (AMPK), a master cellular energy sensor that couples metabolic status to autophagy, mitophagy, glycolysis, lipid metabolism, and inflammatory gene transcription across diverse cell types. PRKAA1 phosphorylates ULK1 at Ser555 to drive BECN1–PI3K complex formation and autophagic flux, a function essential for mitochondrial clearance during erythrocyte maturation and for PINK1/Parkin-dependent mitophagy in neurons [PMID:24988326, PMID:36924562]. In endothelial cells, PRKAA1 sustains aerobic glycolysis to maintain proliferation and barrier integrity—its deletion accelerates atherosclerosis, which is rescued by GLUT1 overexpression—and under high-fat diet conditions it promotes inflammatory gene transcription through an ATP-citrate-lyase/p300 histone acetylation axis [PMID:30405100, PMID:34796475]. In myeloid cells PRKAA1 supports macrophage metabolic fitness and tissue recruitment, while in skeletal muscle its loss derepresses mTOR signaling and promotes intramyocellular lipid accumulation [PMID:33511118, PMID:29288408].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Early work established that PRKAA1/AMPK activation mediates stress-induced proteasomal degradation of ID2 in trophoblast stem cells, linking AMPK to differentiation decisions beyond its canonical metabolic role.\",\n      \"evidence\": \"Pharmacological AMPK and proteasome inhibition with ID2 protein quantification in mouse trophoblast stem cells\",\n      \"pmids\": [\"20876741\", \"20422711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic PRKAA1 knockout confirmation; relies on compound C\", \"Whether the ID2 degradation pathway is α1- or α2-specific was not resolved\", \"Downstream transcription factor targets of ID2 loss not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Genetic deletion of Prkaa1 revealed its non-redundant, cell-autonomous role in ULK1(Ser555) phosphorylation and autophagy-dependent mitochondrial clearance during erythrocyte maturation, establishing a mechanistic link between AMPK catalytic activity and mitophagy in vivo.\",\n      \"evidence\": \"Prkaa1 knockout mice with bone marrow transplant, ULK1 phosphorylation assay, autophagic flux quantification, rapamycin and MitoTEMPO rescue\",\n      \"pmids\": [\"24988326\", \"25483961\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRKAA2 can partially compensate in other tissues was not tested\", \"Direct phospho-site specificity on ULK1 not mapped beyond Ser555\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The upstream activation cascade was extended: CAMKK2 was shown to activate PRKAA1 downstream of CSF1/P2RY6 receptor signaling, linking extracellular cues to PRKAA1-ULK1-dependent autophagy during monocyte-to-macrophage differentiation.\",\n      \"evidence\": \"siRNA knockdown and pharmacological epistasis at CAMKK2, PRKAA1, and ULK1 nodes in primary human monocytes\",\n      \"pmids\": [\"26029847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CAMKK2-PRKAA1 axis operates in tissue-resident macrophage differentiation in vivo not tested\", \"Contribution of AMP-dependent versus calcium-dependent AMPK activation not dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Post-transcriptional regulation of PRKAA1 by miR-181a was demonstrated in the hippocampus, showing that learning-induced miR-181a upregulation suppresses PRKAA1 to modulate mTOR-dependent memory formation.\",\n      \"evidence\": \"Luciferase reporter validation, stereotaxic miR-181a agomir/antagomir injection, AICAR/compound C pharmacological rescue in fear conditioning and object location tasks\",\n      \"pmids\": [\"28814760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type specificity of miR-181a–PRKAA1 axis in hippocampus not resolved\", \"No PRKAA1 conditional knockout in neurons to confirm necessity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Endothelial-specific Prkaa1 deletion revealed a previously unknown pro-glycolytic function: PRKAA1 sustains GLUT1-dependent glycolysis in endothelial cells, maintaining barrier integrity and proliferation in atheroprone vascular regions.\",\n      \"evidence\": \"Endothelial Prkaa1 knockout mice on hyperlipidemic background, ECAR glycolysis measurement, SLC2A1 overexpression rescue, atherosclerosis quantification\",\n      \"pmids\": [\"30405100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PRKAA1 phosphorylation target linking AMPK to GLUT1 trafficking not identified\", \"Relative contribution of glycolysis versus other AMPK metabolic outputs not isolated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The metabolic function of endothelial PRKAA1 was extended to inflammatory transcription: PRKAA1 maintains acetyl-CoA levels via glycolysis and fatty acid oxidation, fueling ATP-citrate-lyase/p300-dependent histone acetylation at inflammatory gene loci under high-fat diet conditions.\",\n      \"evidence\": \"EC-specific Prkaa1 KO mice on HFD, acetyl-CoA quantification, ACLY and p300 inhibitor experiments, metabolic flux assays\",\n      \"pmids\": [\"34796475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific histone marks and genomic loci controlled by this axis not mapped genome-wide\", \"Whether this mechanism operates in other PRKAA1-expressing cell types is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Myeloid-specific Prkaa1 deletion demonstrated that PRKAA1 is required for macrophage metabolic fitness, tissue recruitment, and viability, explaining how its loss attenuates diet-induced metabolic syndrome and atherosclerosis.\",\n      \"evidence\": \"Myeloid Prkaa1 KO mice on HFD/Western diet, flow cytometry for tissue macrophage content, metabolic phenotyping\",\n      \"pmids\": [\"33511118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether macrophage viability defect is due to impaired glycolysis, autophagy, or both not dissected\", \"PRKAA1 versus PRKAA2 contribution in myeloid cells not separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Epitranscriptomic regulation of PRKAA1 was established: FTO removes m6A from the PRKAA1 3′-UTR, preventing YTHDF2-mediated mRNA degradation and thereby increasing PRKAA1 protein levels.\",\n      \"evidence\": \"m6A-RIP, YTHDF2 binding assay, FTO knockdown/overexpression with PRKAA1 mRNA stability measurement in gastric cancer cells\",\n      \"pmids\": [\"36305690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FTO–PRKAA1 m6A axis operates in non-cancer contexts not tested\", \"Specific m6A sites on PRKAA1 mRNA not mapped at nucleotide resolution\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"PRKAA1 was shown to drive PINK1/Parkin-dependent mitophagy in neurons upon fluoride stress, extending its mitophagy-regulatory role beyond erythropoiesis; excessive PRKAA1-driven mitophagy contributes to neuronal apoptosis.\",\n      \"evidence\": \"NaF-treated SH-SY5Y cells and rat model, phosphoproteomics, dorsomorphin inhibition, PINK1/Parkin/TOMM20 Western blotting\",\n      \"pmids\": [\"36924562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRKAA1 directly phosphorylates PINK1/Parkin or acts indirectly not determined\", \"Threshold distinguishing protective from detrimental mitophagy not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the direct phosphorylation substrates through which PRKAA1 controls GLUT1 trafficking and glycolytic flux, the structural basis for α1 versus α2 subunit substrate selectivity, and whether the acetyl-CoA/p300 inflammatory transcription axis operates broadly across PRKAA1-expressing cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of PRKAA1 substrate selectivity determinants\", \"No systematic phosphoproteomics comparing PRKAA1 versus PRKAA2 substrates\", \"In vivo contribution of epitranscriptomic (m6A) regulation of PRKAA1 not assessed outside cancer\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 10]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 3, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [0, 1, 2, 10, 14]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 6, 7, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"complexes\": [\n      \"AMPK heterotrimeric complex (α1βγ)\"\n    ],\n    \"partners\": [\n      \"ULK1\",\n      \"BECN1\",\n      \"CAMKK2\",\n      \"PINK1\",\n      \"PRKN\",\n      \"SLC2A1\",\n      \"ACLY\",\n      \"FTO\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRKAA1 encodes the catalytic α1 subunit of AMP-activated protein kinase (AMPK), a master energy sensor that coordinates cellular anabolism and catabolism in response to metabolic stress. Activated by phosphorylation at Thr-172 by LKB1 under energy stress or by CaMKKβ in response to Ca²⁺ signals [PMID:8910387, PMID:14985505, PMID:16054095], PRKAA1 directly phosphorylates substrates including ACC, TSC2, raptor, and ULK1 to inhibit mTORC1-driven growth, stimulate fatty acid oxidation, promote autophagy and mitophagy, and suppress ferroptosis [PMID:14651849, PMID:18439900, PMID:24988326, PMID:32029897]. These activities underpin diverse physiological roles: PRKAA1-dependent mitophagy is essential for erythrocyte maturation and prevention of hemolytic anemia [PMID:24988326]; endothelial PRKAA1 sustains protective glycolysis and vascular integrity against atherosclerosis [PMID:30405100]; myeloid PRKAA1 modulates macrophage inflammatory polarization by suppressing NF-κB and promoting anti-inflammatory cytokine production [PMID:19050283, PMID:33511118]; and muscle-specific PRKAA1 maintains lipid oxidative capacity and prevents intramyocellular lipid accumulation [PMID:29288408]. Loss of PRKAA1 in erythroid progenitors causes hemolytic anemia with splenomegaly due to failed mitochondrial clearance, a phenotype rescued by rapamycin [PMID:24988326].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of Thr-172 as the single essential activation-loop phosphorylation site on AMPK α resolved how upstream kinase input is transduced into catalytic activation and why AMP dependence requires prior phosphorylation.\",\n      \"evidence\": \"In vitro kinase assay with purified rat liver AMPK; phosphopeptide mapping and site-directed mutagenesis\",\n      \"pmids\": [\"8910387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the upstream kinase (AMPKK) was unknown\", \"Structural basis of AMP-dependent allosteric activation unresolved\", \"Relative contributions of α1 versus α2 isoforms not distinguished\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing LKB1 as the dominant upstream kinase for Thr-172 phosphorylation connected the tumor suppressor LKB1 to energy sensing and explained the near-complete loss of AMPK activity in LKB1-deficient cells.\",\n      \"evidence\": \"In vitro kinase assay; LKB1-knockout MEFs with WT vs kinase-dead LKB1 reintroduction; energy-stress apoptosis rescue\",\n      \"pmids\": [\"14985505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether alternative kinases can compensate in specific tissues remained unclear\", \"The role of LKB1-associated regulatory subunits (STRAD, MO25) in directing specificity toward PRKAA1 vs PRKAA2 unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery of CaMKKβ as a Ca²⁺-dependent, AMP-independent upstream kinase for AMPK revealed a second activation axis, explaining how AMPK can be activated without energy deficit.\",\n      \"evidence\": \"CaMKK inhibitor STO-609; isoform-specific siRNA; Ca²⁺ ionophore stimulation in LKB1-null cells; cell-free kinase assays\",\n      \"pmids\": [\"16054095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of CaMKKβ vs LKB1 in different tissues not quantified\", \"Other potential upstream kinases not excluded\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Positioning PRKAA1 as a required mediator downstream of adiponectin and upstream of ACC phosphorylation and fatty acid oxidation established the first complete hormonal–AMPK–metabolic effector axis in muscle and liver.\",\n      \"evidence\": \"Dominant-negative AMPK epistasis; ACC phosphorylation; fatty acid oxidation and glucose uptake in myocytes\",\n      \"pmids\": [\"12368907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRKAA1 or PRKAA2 is the predominant isoform mediating adiponectin effects in vivo was not resolved\", \"Receptor-to-AMPK signaling intermediates were unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of TSC2 as a direct AMPK substrate linked energy sensing to growth control via mTOR, explaining how energy deprivation suppresses cell size and translation.\",\n      \"evidence\": \"In vitro AMPK kinase assay on TSC2; TSC2-null cell epistasis; cell size and apoptosis measurement\",\n      \"pmids\": [\"14651849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AMPK phosphorylation of TSC2 is sufficient or requires cooperation with other TSC2 kinases\", \"Direct in vivo relevance in tissue-specific contexts not shown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"AMPK-dependent phosphorylation of p53 at Ser-15 connected the metabolic checkpoint to cell-cycle arrest, revealing that persistent AMPK activation can drive senescence rather than just survival.\",\n      \"evidence\": \"AICAR activation; p53-S15 phosphorylation; cell-cycle analysis; p53-null epistasis; glucose deprivation\",\n      \"pmids\": [\"15866171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AMPK phosphorylates p53 directly or via intermediate kinases was not fully delineated\", \"Threshold distinguishing protective arrest from senescence undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of raptor as a direct AMPK substrate that recruits 14-3-3 upon phosphorylation provided a second, TSC2-independent mechanism for mTORC1 inhibition and clarified the multi-pronged nature of AMPK's control over growth.\",\n      \"evidence\": \"Proteomic substrate screen; in vitro kinase assay; 14-3-3 Co-IP; raptor phospho-mutant rescue; cell-cycle analysis\",\n      \"pmids\": [\"18439900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative quantitative contribution of raptor vs TSC2 phosphorylation to mTORC1 suppression unknown\", \"Whether 14-3-3 binding is reversible and how it is terminated unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that PRKAA1 suppresses NF-κB-driven proinflammatory cytokines (TNF-α, IL-6) and promotes IL-10 in macrophages established a direct immune-regulatory role for the α1 isoform beyond metabolic regulation.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function (dominant-negative and constitutively active AMPKα1) in macrophages; cytokine ELISA; IκB-α and Akt phosphorylation\",\n      \"pmids\": [\"19050283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation substrates mediating anti-inflammatory output not identified\", \"In vivo relevance in infection or sterile inflammation not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that PRKAA1 is essential for ULK1-Ser555 phosphorylation, BECN1 complex formation, and mitophagic clearance of mitochondria during erythropoiesis — with knockout mice developing hemolytic anemia — established a non-redundant physiological requirement for the α1 isoform in terminal differentiation.\",\n      \"evidence\": \"Prkaa1 knockout mice; bone marrow transplantation; ULK1-BECN1 Co-IP; mitochondrial content and ROS measurement; rapamycin rescue\",\n      \"pmids\": [\"24988326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why PRKAA2 cannot compensate for PRKAA1 in erythroid cells is mechanistically unresolved\", \"Precise signaling events linking PRKAA1 to ULK1-BECN1 assembly not fully mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Epistatic pathway dissection placed CaMKK2–PRKAA1–ULK1 as a required signaling axis for CSF1-induced autophagy during monocyte-to-macrophage differentiation, extending the mitophagy role to myeloid lineage commitment and identifying therapeutic restoration in CMML.\",\n      \"evidence\": \"Sequential siRNA knockdown of CAMKK2, PRKAA1, ULK1 in human monocytes; autophagy flux; differentiation markers; P2RY6 agonist rescue in CMML patient cells\",\n      \"pmids\": [\"26029847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRKAA1-dependent autophagy is required for all macrophage subtypes or only M-CSF-derived\", \"Long-term efficacy of P2RY6 agonism in CMML patients unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Muscle-specific Prkaa1 deletion revealed that the α1 isoform maintains mitochondrial oxidative gene expression and prevents intramyocellular lipid accumulation, with mTOR hyperactivation as a contributing mechanism, extending PRKAA1's tissue-specific roles to skeletal muscle lipid homeostasis.\",\n      \"evidence\": \"Muscle-specific Prkaa1 knockout mice; HFD feeding; triglyceride and gene expression; mTOR pathway immunoblot\",\n      \"pmids\": [\"29288408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of PRKAA1 vs PRKAA2 in skeletal muscle lipid metabolism not clarified\", \"Whether mTOR inhibition alone rescues the lipid phenotype not tested\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Endothelial-specific Prkaa1 deletion showed that PRKAA1-driven glycolysis is required for endothelial proliferation and barrier integrity, and its loss accelerates atherosclerosis — a phenotype rescued by GLUT1 overexpression — establishing the α1 isoform as a vascular metabolic gatekeeper.\",\n      \"evidence\": \"EC-specific Prkaa1 KO mice; atherosclerosis quantification; GLUT1 rescue; ECAR measurement; barrier assays\",\n      \"pmids\": [\"30405100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets through which PRKAA1 upregulates GLUT1 expression not identified\", \"Interaction with endothelial PRKAA2 not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that AMPK inhibits ferroptosis via ACC phosphorylation and consequent reduction of PUFA biosynthesis linked the classical AMPK-ACC axis to a novel cell death modality and provided in vivo validation in renal ischemia-reperfusion injury.\",\n      \"evidence\": \"Genetic AMPK inactivation; ferroptosis and lipidomic analysis; ACC phosphorylation; renal IRI model\",\n      \"pmids\": [\"32029897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRKAA1 or PRKAA2 is the dominant isoform in ferroptosis suppression not distinguished\", \"Other AMPK substrates contributing to ferroptosis resistance not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Dual context-dependent vascular roles emerged: endothelial PRKAA1 deficiency in HFD reduces acetyl-CoA and p300-mediated inflammatory transcription (improving metabolic syndrome), while myeloid PRKAA1 deficiency impairs macrophage metabolic fitness and tissue recruitment (reducing atherosclerosis), revealing opposing cell-type-specific outcomes.\",\n      \"evidence\": \"EC-specific and myeloid-specific Prkaa1 KO mice on HFD; acetyl-CoA and p300 activity; macrophage metabolomics; flow cytometry; atherosclerosis and metabolic phenotyping\",\n      \"pmids\": [\"34796475\", \"33511118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same kinase produces pro- vs anti-inflammatory outcomes in different cell types is mechanistically incomplete\", \"Interaction between endothelial and myeloid PRKAA1 in the same disease model not examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Outstanding questions include: the structural basis for α1 vs α2 isoform substrate specificity; how PRKAA1 integrates multiple upstream signals to produce context-dependent (protective vs pathological) outcomes in different tissues; and whether the tendon maintenance and neuronal memory functions represent conserved or tissue-specific AMPK signaling modules.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of full-length α1β1γ1 with physiological substrate bound\", \"Isoform-specific interactomes not comprehensively mapped\", \"Causal human genetic variants in PRKAA1 linked to Mendelian disease not yet reported\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6, 8, 17]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 3, 4, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [4, 6, 7, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 6, 7, 15]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8, 10, 21, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 14, 17, 22]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 19]}\n    ],\n    \"complexes\": [\n      \"AMPK (α1β1γ1 / α1β2γ1 heterotrimeric complex)\"\n    ],\n    \"partners\": [\n      \"STK11\",\n      \"CAMKK2\",\n      \"RPTOR\",\n      \"TSC2\",\n      \"ULK1\",\n      \"BECN1\",\n      \"ACACA\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}